Press releaseBusiness Wire
Alto Neuroscience
ANRO · NYSE
$24.41+$1.59 (+6.97%)TodayMarket closed ·
Prev close $22.82
Latest news
- Press releaseBusiness Wire
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
- Press releaseBusiness Wire
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseBusiness Wire
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
- Press releaseBusiness Wire
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
- Press releaseBusiness Wire
Alto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of Directors
- Press releaseBusiness Wire
Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award
- Press releaseBusiness Wire
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Press releaseBusiness Wire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
- Press releaseBusiness Wire
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting
- Press releaseBusiness Wire
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
- NewsAvi Kapoor
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- Press releaseBusiness Wire
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements
- News
Earnings Scheduled For March 16, 2026
- Press releaseBusiness Wire
Alto Neuroscience Announces $120 Million Private Placement Financing
- Press releaseBusiness Wire
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights
- Press releaseBusiness Wire
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- Press releasePRNewswire
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
- Press releaseBusiness Wire
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
- Press releaseBusiness Wire
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia
- Press releaseBusiness Wire
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Replimune Group, Inc. (REPL), and Fly-E Group, Inc. (FLYE)
- Press releaseBusiness Wire
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression
- Press releaseBusiness Wire
Alto Neuroscience Presents New Data at the 64th Annual Meeting of the American College of Neuropsychopharmacology
- Press releaseBusiness Wire
Alto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Alto Neuroscience, Inc. (ANRO), Atkore Inc. (ATKR), Dow Inc. (DOW), and Fly-E Group, Inc. (FLYE)
- NewsAvi Kapoor
Jazz Pharmaceuticals, Sigma Lithium, Zymeworks And Other Big Stocks Moving Higher On Monday
- Press releaseBusiness Wire
Alto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business Highlights
- Press releasePRNewswire
NYSE Content Advisory: Pre-Market Update + Government Shutdown Nears End After 42 Days
- Press releaseBusiness Wire
Alto Neuroscience to Participate in Upcoming Investor Conferences
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
- Press releaseGlobe Newswire
ALTO ALERT: Bragar Eagel & Squire, P.C. is Investigating Alto Neuroscience, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- Press releaseGlobe Newswire
Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders
- NewsAvi Kapoor
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
- NewsVandana Singh
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
- NewsAvi Kapoor
Nasdaq Down 2%; US Crude Stocks Increase
- NewsVandana Singh
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
- NewsAvi Kapoor
Gold Moves Lower; AT&T Earnings Top Views
- NewsAvi Kapoor
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
- NewsAvi Kapoor
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.